Saffro-Calm Plus Spray 1 fl oz – 45 serv (P1080-S)
Patient One Saffro-Calm PlusĀ oral spray is formulated with a unique and synergistic combination of botanicals to calm feelings of occasional stress without drowsiness. Because the botanicals in Saffro-Calm Plus have been shown to interact with the body’s endocannabinoid system (ECS), this formula is part of our ECS Synergy⢠series.
Our pleasant tasting spray is for oral use, to be taken by mouth, and may be used by adults and adolescents.Ā Saffro-Calm PlusĀ is convenient to carry when on the go or to easily access on a bedside table. For best results use Saffro-Calm Plus consistently, morning and evening, approximately every 12 hours.
Key Ingredients
AffronĀ® Saffron, in more than 5 published human clinical studies, has been shown as effective at a low daily dose of 28 mg to calm occasional irritability and stress, promote mental balance, maintain a healthy mood and to support restful sleep. Made from Spanish saffronĀ (Crocus sativus), affron’s patented formulation is standardized to provide 3.5% LepticrosalidesĀ®, a complex of bioactive compounds.
Affron’s dual mechanisms of action include:
- reuptake inhibition of dopamine, norepinephrine and serotonin, increasing the concentration of these neurotransmitters in the synaptic cleft of neurons, thereby improving mood balance, and
- antioxidant effect against the excessive oxidative stress produced during the stress process in the central nervous system.
Scientific studies have associated saffron with modulation of the body’s endocannabinoid system.
Echinacea AngustifoliaĀ is also included for added support in reducing occasional tension and promoting a relaxed, positive mood. While this herb is commonly associated with immune system support, the root extract in our formula contains alkamides along with echinacosides. It has been shown that alkamides bind significantly to and activate the body’s cannabinoid receptors in the ECS.
AlkamidesĀ are bioactive compounds that show structural similarity with anandamide. Anandamide is a neurotransmitter that binds to cannabinoid receptors in the brain and body, stimulating a sense of happiness and mental balance. Anandamide is a little-known brain chemical that’s been called the ābliss moleculeā for the role it plays in producing feelings of happiness.

Supplement Facts
| Serving Size:4 Sprays (0.66 mL) | |||
| Servings Per Container: 45 | |||
| Amount Per Serving | % Daily Value** | ||
|
AffronĀ®: saffron (Crocus SativusĀ L.) |
28 | mg | ā |
|
Echinacea angustifoliaĀ extract (root) |
30 | mg | ā |
| ā Daily Value not established. | |||
| Contains:
deionized water, wildflower honey, natural mint flavor, citric acid |
|||
|
Made with ingredients that areĀ free of:Ā milk, egg, fish, peanuts, crustacean shellfish, soy, tree nuts, wheat, yeast, gluten, sesame, GMOs. Does not contain hemp. |
|||
| Trademarks:
Affron® and Lepticrosalides® are registered trademarks of Pharmactive Biotech Products, S.L.U. |
|||
Suggested Use
Adults and adolescents age 12 and up, take 1 serving orally (4 sprays) in divided doses (2 sprays in the morning and 2 sprays in the evening). For best results, use consistently approximately every 12 hours to ensure the body has an effective amount at all times.
Warnings
This product is contraindicated if you are pregnant or nursing or have a known allergy to plants of the daisy family. If taking any medications, consult doctor before use. Discontinue use and consult doctor if any adverse reactions occur. Keep out of reach of children.
Ā References
- Almodóvar P, et al. Evidence-Based Complementary and Alternative Medicine. 2020; 1ā8.
- Jackson P. A., et al. Frontiers in Nutrition, 2021; 7:606124.
- Kell G et al. Therapies in Medicine, 2017; 33:58ā64.
- Lopresti, A. L. Journal of Affective Disorders, 2015;181:24ā32.
- Lopresti A. L., et al. 2021; 27(2):66.
- Lopresti A. L., et al. Journal of Affective Disorders. 2018; 232:349ā357.
- Lopresti A. L., et al. Sleep Medicine. 2021; 86:7-18.
- Lopresti A. L., et al. Journal of Clinical Sleep Medicine. 2020; 16(6):937ā947.
- Nishide A., et al. Japan Pharmacology and Therapeutics, 46(8):1407ā1415.
- Woelkart K, et al. Planta Medica, 2007; 73(7):615-623.





